fluorobenzenes has been researched along with Liver Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Everett, BM; Glynn, RJ; MacFadyen, J; Mora, S; Ridker, PM | 1 |
| Lasseter, KC; Martin, PD; Mitchell, P; Schneck, DW; Simonson, SG; Warwick, MJ | 1 |
| Guthrie, RM; Martin, DR | 1 |
1 review(s) available for fluorobenzenes and Liver Diseases
| Article | Year |
|---|---|
The safety of rosuvastatin: effects on renal and hepatic function.
Topics: Animals; Chemical and Drug Induced Liver Injury; Fluorobenzenes; Humans; Kidney; Kidney Diseases; Liver; Liver Diseases; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2007 |
2 trial(s) available for fluorobenzenes and Liver Diseases
| Article | Year |
|---|---|
Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER).
Topics: Aged; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Hematuria; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Diseases; Male; Middle Aged; Odds Ratio; Proportional Hazards Models; Pyrimidines; Rosuvastatin Calcium; Sleep Initiation and Maintenance Disorders; Sulfonamides; Treatment Outcome | 2014 |
Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment.
Topics: Adult; Area Under Curve; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |